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There is an often unspoken truth behind the course of scientific investigation that involves not what is necessarily academically
worthy of study, but rather what is scientifically worthy in the eyes of funding agencies. The perception of worthy research is, as
cost is driven in the simplest sense in economics, often driven by demand. Presently, the demand for novel diagnostic and therapeutic protein biomarkers that possess high sensitivity and specificity is placing major impact on the field of proteomics. The focal
discovery technology that is being relied on is mass spectrometry (MS), whereas the challenge of biomarker discovery often lies
not in the application of MS but in the underlying proteome sampling and bioinformatic processing strategies. Although biomarker
discovery research has been historically technology-driven, it is clear from the meager success in generating validated biomarkers
that increasing attention must be placed at the pre-analytic stage, such as sample retrieval and preparation. As diseases vary, so
do the combinations of sampling and sample analyses necessary to discover novel biomarkers. In this review, we highlight different
strategies used toward biomarker discovery and discuss them in terms of their reliance on technology and methodology.

INTRODUCTION
Protein biomarker discovery
requires multidisciplinary strategies
that incorporate intelligent sample
collection, processing, data acquisition, and analysis (see Reference 2).
Protein identification has historically
been accomplished by Edman degradation. Although an arguably powerful
technology, it suffers both in terms of
throughput and scope, as proteins can
only be sequenced consecutively and
only after appreciable purification.
Furthermore, even if these criteria are
fulfilled, this technology falls short,
in that it provides no facile translation
to routine protein assay development.
Improvements in biomarker assays
have all relied on the development
and use of high affinity reagents
(i.e., antibodies). The development
of modern separations coupled with
advanced mass spectrometry (MS)
has ushered in a new paradigm in the
throughput and scope with which
proteins can be identified and characterized. These proteomic-scale capabilities now enable thousands of proteins
to be identified from complex mixtures

(1). Indeed, no other technology
parallels the capability of MS in the
identification of proteins from complex
proteomic samples, such as serum,
plasma, urine, or cerebrospinal fluid
(CSF). It is for these reasons that
conventional wisdom suggests that
through application of these new tools,
novel and specific disease biomarkers
will be identified. Accordingly, the
recent past has seen an exponential rise
in data acquisition (i.e., MS) and data
analysis (i.e., computer hardware and
software) capabilities, while it may be
argued that commensurate advances in
sample collection and processing have
lagged. The increasing power of MS
and bioinformatic tools often results
in experimental designs that are overly
dependent on technology and suffer
from lack of imaginative sample preparation. As shown in Figure 1, there is
often an inverse relationship between
the complexity of sample preparation
and the amount of data acquired or
the sophistication of the bioinformatic
analysis. Simply put, minimal sample
preparation prior to MS analysis will
require more data acquisition and more
sophisticated bioinformatic analysis.

There is, however, a direct correlation
between the amount of data acquired
and the sophistication of the bioinformatic analysis.
ANALYTICAL SAMPLING OF
BIOFLUIDS
In the simplest sense, the goal of
protein biomarker discovery is to
identify a protein or panel of proteins
that distinguish patients afflicted
with a particular disease from healthy
individuals (2). While the premise
seems simple enough, achieving
this goal has not been a trivial
pursuit. Ideally, such a biomarker or
biomarkers would be assayable in
biological samples obtained through
minimal invasion. Biofluids such
as urine, serum, and plasma readily
fulfill such criteria and are routinely
collected during physical examinations. Unfortunately, these biofluids
represent an extremely difficult matrix
to characterize, even by the most
advanced MS technologies. These
difficulties are clear if one considers
the physiological and analytical
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Figure 1. Graphical representation of the dependency of the mass spectral data acquisition
and bioinformatic effort based on the level of
experimental focus in proteomic investigations. As illustrated, increased experimental focus results in a corresponding decrease in both
mass spectrometry (MS) data acquisition and
bioinformatic effort.

challenges in discovering, for example,
a tumor-specific protein biomarker in
serum. Assume that a population of
tumor cells secretes an aberrant protein
into the circulatory system. The blood,
collected from a vein at the inner elbow
and from which the serum sample
is prepared, is derived from a 7.5-L
circulatory system that encompasses
approximately 100,000 km of veins,
arteries, and capillaries. While the
local concentration of the biomarker
may be high in the microenvironment
of the tumor, its travels take it through
thousands of kilometers of biological
highways until it reaches the point
of extraction (i.e., inner elbow). This
journey will have many confounding
effects that present several analytical
challenges to its facile detection, the
most obvious of which is dilution. The
high concentration of the biomarker
within the vicinity of the tumor
will be dramatically decreased as it
moves within the circulatory system.
Since the activity level of proteases
in blood is high, the biomarker may
also be digested into a variety of
different fragments prior to collection.
Therefore the primary sequence, and
potentially the functional significance,
of the biomarker can radically change
between the point of entry into the
circulation system and collection.
Probably the most challenging
aspect of discovering biomarkers in
biofluids such as serum and plasma is
800 BioTechniques

their proteomic complexity (3). While
the exact number of proteins is not
known, it has been estimated that has
many as 105–106 different species may
be constituents in the blood proteome.
Adding to that complexity, the blood
proteome is in a persistent state of
flux, with materials being exchanged
with healthy cells and proteins being
released from necrotic and apoptotic
cells. Furthermore, this complexity
is not simply a function of the sheer
numbers of proteins, but also the
dynamic range of their concentrations
estimated conservatively at minimally
ten orders of magnitude (4).
With these factors to consider,
obviously the ability to comprehensively characterize these biofluid
proteomes is a critical first step in the
hope of identifying clinically significant biomarkers. In the recent past,
there have been a number of studies
utilizing different separation technologies followed by MS protein identification to characterize these proteomes
(5). The two primary separation
methods for obtaining comprehensive
proteome coverage have been twodimensional polyacrylamide gel
electrophoresis (2D-PAGE) and multidimensional liquid chromatography
(LC) (i.e., strong cation exchange
LC followed by reversed-phase LC).
Research conducted at Large Scale
Biology Corporation (LSBC; Vacaville,
CA, USA) has been instrumental in
highlighting the utility of 2D-PAGE/
MS analyses in biofluid proteomics.
Studies conducted at LSBC demonstrated the resolution of over 1400
and 3700 distinct protein spots on
2D-PAGE gels from urine and serum
samples, respectively, resulting in the
respective identification of 150 and 325
unique proteins (6,7). Investigations
using multidimensional LC coupled
to MS analysis have typically resulted
in the identification of 1500–2000
proteins in serum or plasma and 100–
250 proteins in urine (8,9). Although it
might be argued that 2D-PAGE results
in fewer protein identifications, the
upshot is that it provides quantitative
information in comparative analyses
through the comparison of stained
protein spot intensities and information related to protein isoforms
and posttranslational modifications.

Multidimensional fractionation allows
more protein identifications but
suffers from less rigorous quantitative
comparisons that are based typically
on the number of peptides observed
and/or their raw ion current for a given
protein. While the numbers of proteins
identified using either method do not
approach the expected complexity
of the given biofluid, they do provide
orders of magnitude more coverage
and information than available prior
to the proteome era and warrant the
use of these technologies in biomarker
discovery.
In many ways, biomarker discovery
using such technologies is a case of
the proverbial needle-in-the-haystack
expedition without knowing what the
haystack or the needle looks like. The
hope is that the data reveal a handful
of proteins that distinguish disease and
fulfill the necessary criteria to move
to a validation stage using expanded
clinical cohorts. There has been a
tremendous amount of resources, both
in terms of time and money, devoted to
global biofluid analysis for biomarker
discovery. While there have been many
potentially useful biomarkers put
forth in the literature, there have been
none that have been validated to meet
Food and Drug Administration (FDA)
requirements. Does this mean the
leveraging of MS and bioinformatics
to analyze complex biofluid samples
has been a waste of time? Absolutely
not! The analytical advances made in
the development of instrumentation
with greater acquisition speed, sensitivity, dynamic range, and resolution,
as well as bioinformatic tools that
more accurately identify proteins,
have allowed a greater understanding
of the proteome content of many
biofluids. We are only now beginning
to understand changes in the proteomes
common to many disease conditions
and in a sense recognizing just what the
haystack looks like.
SOURCES OF CLINICAL
SAMPLES
An ideal biomarker would be found
in a biological specimen that can be
obtained noninvasively and, in the case
of cancer, be as directly proximal to the
Vol. 40, No. 6 (2006)

underlying tumorigenesis as possible
to endow high levels of specificity and
sensitivity to the disease. Biofluids
such as serum, plasma, urine, and CSF
have been the predominant choice for
biomarker discovery. One obvious
reason is their accessibility; acquiring
tumor biopsies from patients is invasive,
costly, and impractical. Another reason
arises from a forward thinking vision for
development of routine clinical assays.
Unfortunately, the sheer complexity
of these biofluids prevents direct
association of a protein identified from a
proteomic study to its site of origination.
Fortunately, recent developments in
utilizing new techniques that enable
sampling of material closer to the site
of interest may provide more directed
routes to the identification of biomarkers
suitable for clinical validation.
Formalin-Fixed Paraffin-Embedded
Tissues
To correlate the biomarker-tumor
connection, tumor biopsies have to be
performed and other biochemical or
imaging methods, such as immunohistochemistry, also need to be performed
to validate the site of origination of a
given protein biomarker. The extraction
of tumor material either surgically or
through a needle biopsy, however, is
highly invasive, and the costs (both in
terms of time and money) of obtaining
sizable cohorts of samples from willing

donors makes such studies almost
impractical for discovery-driven
biomarker research. Fortunately, there
is a vast archive of tumors in the form
of formalin-fixed paraffin-embedded
(FFPE) tissues. While these tissues
have been routinely used for immunohistochemistry, in situ hybridization
studies, and more recently, in arraybased genomic and transcriptomic
analyses, their utility in discoverydriven proteomics has been essentially
nonexistent. The general belief has
been that the fixation procedure results
in formaldehyde-induced inter- and
intramolecular covalent cross-links
that renders proteins intractable to
downstream fractionation, digestion,
and MS analysis (10).
Recently, three studies have been
reported that demonstrate the potential
of using FFPE samples in discoverydriven proteomics (11–13). While slight
overall differences exist, two of these
combined enzymatic digestion with
liquid chromatography-tandem mass
spectrometry (LC-MS/MS) analysis
of proteins extracted from FFPE
samples. In one study, this capability
was demonstrated through fixation
of a confluent culture of follicular B
cell lymphoma cells (SUDHL-4) (11).
Lysis buffer was added to 10 sections
cut from the fixed sample to extract the
protein complement of the cells, which
was subsequently digested into peptides
using either trypsin or glutamic-C

Figure 2. Characterization of formalin-fixed paraffin-embedded (FFPE) prostate tissue by liquid chromatography-tandem mass spectrometry (LC-MS/MS). (A) In this study (Reference 12),
cells from regions of prostate cancer (PCa), stroma, and benign prostatic hyperplasia (BPH) were laser
capture microdissected from the tissue. Peptides were extracted from each cell type and analyzed by
LC-MS/MS.
Vol. 40, No. 6 (2006)

endopeptidase (Glu-C). Analysis of the
samples by LC-MS/MS resulted in the
identification of 324 proteins from two
or more unique peptides. The identification of important signaling proteins
such as Raf-B, JAK1, STAT1, and
protein kinase C (PKC) was confirmed
by immunoblot analysis.
In a clinically relevant application,
another study combined the use of
laser capture microdissection with
proteomic analysis to investigate
prostate cancer (PCa) and benign
prostatic hyperplasia (BPH) from
cells captured from archived FFPE
prostate tissue (12). Tryptic peptides
were extracted from each of the histologically distinct cells and separately
analyzed by LC-MS/MS, as illustrated
in Figure 2. In total, 1156 and 702
unique proteins were identified from
the PCa and BPH FFPE tissue extracts,
respectively. Differences in protein
abundance from the PCa and BPH cells
were determined by comparing the
number of unique peptides identified
from a specific protein. A variety
of prostate-related proteins, such as
prostatic acid phosphatase (PAP), Raf
kinase inhibitor protein (RKIP), and
most notably prostate-specific antigen
(PSA), were identified in both sample
types by multiple peptides (Table 1). In
contrast, growth differentiation factor
15 (GDF-15) was only identified by
four unique peptides in PCa cells. This
result is in agreement with a previous
study that showed an up-regulation of
GDF-15 in PCa cells compared with
high-grade prostatic intraepithelial
neoplasia (hPIN) cells (14).
These studies also evaluated the
effect of FFPE processing versus more
commonly used fresh/frozen cells and
tissues, by comparing the proteomes
from each sample source. Comparison
of FFPE and fresh SUDHL-4 cells
resulted in the identification of 324
and 512 proteins, respectively (11),
while a comparison of 30,000 cells
microdissected from FFPE and frozen
mouse liver resulted in similar numbers
of protein identifications from each
sample (approximately 88% as many
proteins could be identified from the
FFPE sections as from frozen sections)
(12). Besides the number of peptides
and proteins identified, what was
particularly encouraging in the analysis
BioTechniques 801
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of the FFPE and frozen tissue was the
similarity in the base-peak chromatograms (BPC) and the tandem mass
spectra obtained from both samples.
The similarities in the BPC and the
tandem mass spectra suggest that the
population of proteins extracted from
each sample type is comparable.
Taken together, these observations
suggest that the vast archive of FFPE
tissues, a heretofore unexplored clinical
sample source, may provide a valuable
new avenue for biomarker discovery.
This new accessibility of FFPE tissues
to proteomic research could catalyze a
shift in the manner in which candidate
biomarkers are identified for validation
in biofluids (e.g., in cancer research).
An alternate option to the present
paradigm of analyzing biofluids to
identify differentially abundant protein
biomarkers related to disease may
be to first analyze clinical cohorts of
FFPE tumor tissues, rendering a subset
of proteins proximal to the disease
mechanism that can be validated via
assay in the appropriate biofluid in
expanded clinical cohorts.
This new paradigm has many
potential advantages over standard
biomarker identification/evaluation
protocols. First, potential biomarkers
discovered using MS approaches could
be validated by immunohistochemistry within a section cut from the
same tumor. Second, if the presence
of the tumor-related proteins can be
validated in a corresponding biofluid,
the confidence in linking the origin
of the proteins to the diseased tissue
is greatly increased than if they were
simply identifying the proteomic
survey of the biofluid alone. While

not discussed in great depth, a major
problem in attempting to find diseasespecific biomarkers in serum or plasma
is that acute phase and inflammatory
response proteins are typically upregulated under many different conditions, adding to the complexity of the
biofluid, but having limited utility for
diagnostic purposes. Direct analysis
of the tumor should also ameliorate
the background differences associated
with these proteins that are commonly
observed in the analysis of serum or
plasma from disease-stricken patients.
Organ Perfusion

A clever strategy for eliminating
the complexity of these biofluids and
permitting the identification of proteins
that may be shed or secreted from the
diseased tissue was recently described by
Koomen et al. (15). In this study, isolated
beating hearts were dissected from rats
and immediately perfused for approximately 5 min to remove blood from the
organs. The hearts were then subjected
to ischemic conditions and reperfused.
The effluent from this perfusion was
collected in various fractions that were
subsequently analyzed by LC-MS/MS
for protein identification and sodium
dodecyl sulfate PAGE (SDS-PAGE)
to verify the removal of background
serum/plasma proteins. The SDS-PAGE
results showed a dramatic decrease (i.e.,
at least 90%) in the level of albumin in
the perfused samples collected after
blood had been removed from the heart.
Analysis of the perfusion effluent by
LC-MS/MS resulted in the identification
of 342 proteins. Approximately onethird of the proteins were cytoplasmic in
origin, while another third were
common resident serum/plasma
proteins. Several biomarkers
Table 1. Total Number of Peptides Identified
for myocardial injury such
PCa
BPH
Stroma
Protein
aspartate aminotransferase,
1
PSA
10
16
creatine kinase MB, cardiac
PEBP
12
7
3
troponin I, cardiac troponin T,
31
28
0
PAP
glycogen phosphorylase, and
heart fatty acid binding protein
4
0
0
GDF-15
(FABP) were identified in the
Comparative analysis of the proteomes showed that proeffluent. Other potentially
teins such as prostate-specific antigen (PSA), prostatic
acid phosphatase (PAP), and phosphatidylethanolamine
valuable markers of myocardial
binding protein (PEBP) were highly represented within both
ischemia were also identified
prostate cancer (PCa) and benign prostatic hyperplasia
such as myotrophin, neuropro(BPH) cells, based on total peptide count. Growth-differentiation factor 15 (GDF-15), however, was observed exclutective protein DJ-1, atriopepsively with PCa cells.
tigen, which is the precursor for
802 BioTechniques

atrionatriuretic peptides, and the AMP
phosphoramidate-hydrolyzing enzyme
HINT1.
Obviously this technology has some
drawbacks in application to human
patients, primarily in the ability to
acquire samples as well as the cellular
heterogeneity of organ systems.
Accordingly, the investigators proposed
some intriguing applications of this
sampling technology particularly in the
analysis of human xenograft tumors
in encapsulated organs of athymic
or immunodeficient mice (15). This
technique should allow tumor-specific
(human) and host response (mouse)
protein biomarkers to be easily discriminated.
Functional Proteomic Assays
While not applicable to every type
of study, using sample preparation
methods to target a specific functional
characteristic can often facilitate the
discovery of a biomarker(s). These
directed studies rely heavily on sample
preparation techniques but do not
require excessive MS data acquisition
nor the need to burden the bioinformatic
analysis to find the desired compounds
among a complicated matrix. For
instance, Dr. Benjamin Cravatt and
coworkers have been leaders in
developing activity-based protein
profiling (ABPP) for the discovery of
functional states specific to tumors
(16). This technology uses chemical
probes directed toward the active
sites of specific classes of enzymes
to detect functional changes in entire
proteome samples. Recently this group
teamed up with Dr. John Yates’ group
to complement their functional assay
capabilities with MS identification of
the enzymes that were detected.
In one such application, this effort
used fluorophosphonate (FP)-based
ABPP probes that target serine hydrolases, a diverse class of enzymes that
have been implicated in cancer (17). In
the first phase of the study, rhodaminetagged FP-ABPP probes were added
to 12 μg protein obtained from homogenized breast tumor tissue sections
and then analyzed by SDS-PAGE with
fluorescence detection, as shown in
Figure 3A. The gel image revealed the
profile of changes in serine hydrolase
Vol. 40, No. 6 (2006)

activity across different breast tumors.
While the image demonstrated different
activity profiles from different tumors,
direct identification of the enzymes
linked to these changes was not possible
using this analytical platform.
To redress this deficiency, they
employed a biotinylated FP-ABPP probe
(instead of rhodamine-tag) as shown in
Figure 3B. The probe-labeled proteins
were enriched using avidin-conjugated
beads. After on-bead trypsin digestion,
the peptide mixture was analyzed by
multidimensional LC-MS/MS. Over 50
serine hydrolases were identified in the
tumor proteomes using the biotin-FP
ABPP probe. Only a few of the same
activities were observed in the control
reactions in which the probe was not
added to the proteome sample. These
enzymes included proteases, lipases,
esterases, several proteasome subunits,
and at least 15 uncharacterized hydrolases.
For quantitation, the spectral count
(e.g., number of peptide identifications
by MS/MS) for each hydrolase was
averaged for the two different breast
cancer samples. Several enzymes were
identified that had at least a 3-fold
change in activity among the breast
cancer specimens. For example, fibroblast activation protein, KIAA1363 and
platelet-activating factor acetylhydrolase
2 were elevated in estrogen receptor/
progesterone receptor double negative
[i.e., ER(-)/PR(-)] tumors compared
with either ER(+)/PR(+) tumors or
normal breast tissue. Other enzyme
activities such as thrombin, dipeptidylpeptidase IV, and hormone-sensitive
lipase, however, were found to be higher
in normal breast tissue. While this study
focused on the identification of changes
in serine hydrolase activity, a number of
functional probes are presently available
for hypothesis-driven analyses of
functional changes in tumor cells.
Cell-Based Assays
Cell-based assays are widely used in
biological discovery (18); however, their
combination with MS for biomarker
discovery has been limited. In general,
cell-based assays are used to determine
the effect of a known compound on
cells in culture or to attempt to find
novel compounds within extracts that
Vol. 40, No. 6 (2006)

A

B

Figure 3. Combination of activity-based protein profiling (ABPP) and mass spectrometry (MS)based proteomic profiling to identify specific activities within complex human samples. (A) A rhodamine (Rh)-tagged ABPP probe is used to isolate species that contribute a specific enzymatic activity
from a proteome. The isolated proteins are then resolved by one-dimensional electrophoresis to provide
enzyme activity signatures. (B) In the second phase, the same ABPP probe tagged with biotin (B) is then
used in combination with avidin chromatography to extract the proteins giving rise to the specific activity. The extracted proteins are tryptically digested and analyzed by multidimensional liquid chromatography-MS, for identification and to estimate their respective levels. m/z, mass-to-charge ratio.

produce an effect. Unfortunately, there
has not been much research showing a
combination of cell-based assays and
MS to discover biomarkers in biofluids.
An excellent example of combining
a cell-based assay with multidimensional fractionation and MS analysis
was demonstrated by the discovery of
a biomarker for interstitial cystitis (IC)
(19). Interstitial cystitis (which affects
approximately one million Americans) is
a chronic, debilitating, bladder disorder
that results in the thinning of the bladder
epithelial cell lining (20). This disorder
is typically diagnosed only by exclusion
of other maladies followed by a bladder
biopsy under general anesthesia. It was
discovered in the 1990s that the urine of
patients with IC contained a factor that
inhibited bladder epithelial cell growth
in culture. This antiproliferative factor
(APF) was also found in the supernatant
of epithelial cells in culture explanted
from the bladders of IC patients, but not
from healthy individuals (20). The true
molecular nature (e.g., identity) of APF
was not discovered, however, until 2004
(19).
To discover the identity of APF,
the groups involved used several

chromatographic steps and a cellbased assay to track APF through the
various collected fractions, scored by
measuring [3H]-thymidine incorporation into cultured bladder epithelial
cells (an indicator of inhibition of cell
proliferation) as illustrated in Figure
4 (19). The fraction possessing the
APF activity was graduated through
the various chromatographic steps to
increase its fold-enrichment, which was
subsequently analyzed by LC-MS/MS.
After a series of validation steps that
included comparison of synthetically
generated molecules with structures
approximating the isolated molecule,
APF was validated as a nine-residue
sialoglycopeptide. Subsequent clinical
validation demonstrated the unique
nature of APF in that the transcript
that gives rise to this peptide is solely
present in the urine of patients with IC
and not in that obtained from healthymatched controls.
Considering the structure of APF,
it is highly unlikely that it could have
been identified in a global analysis
comparing urine from IC and healthy
patients using conventional proteomic
strategies. Indeed, most global studies
BioTechniques 803
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focus on comparing quantitative
changes in unmodified, tryptic peptides
derived after proteome digestion. The
very nature of APF, namely a glycosylated, nontryptic peptide, would have
obviated its identification, particularly
when one considers the current guidelines being established in the proteomic
community (www.mcponline.org/misc/
ParisReport.shtml). The discovery of
the structure of APF required a large
effort in sample preparation, but in turn
required a single LC-MS/MS experiment. The bioinformatic burden on the
structure determination was accord-

ingly slight as well, as the tandem
mass spectrum was interpreted de
novo. Validation of the final structure
also required minimal MS and bioinformatics support, but instead relied
on techniques such as lectin chromatography and synthetic chemistry.
Ultimately the successful identification
of this important biomarker for IC
depended on the cell-based assay to
pinpoint the activity of APF in various
chromatography fractions. The entire
process is analogous to separating “the
needle from the haystack” prior to MS
identification.

Figure 4. Incorporation of chromatography and a cell-based assay to aid in the identification of
the antiproliferative factor (APF) for interstitial cystitis (IC). Fractions were collected during each
chromatographic separation and tested for their ability to inhibit bladder epithelial cell proliferation in
vitro. Fractions containing APF activity were then promoted to the next chromatographic step until the
enrichment of APF was high enough to enable it to be identified by mass spectrometry and de novo sequencing. m/z, mass-to-charge ratio.
804 BioTechniques

CONCLUSIONS
Proteomics currently exists in a
discovery and survey era where MS,
and its affiliate technologies, is focused
on identification of candidate novel,
biofluid-based biomarkers for various
disorders. As shown through the
variety of examples presented in this
review, the challenges are immense,
and there is often a trade-off between
the amount of effort placed in sample
preparation, the amount of MS data
acquisition, and the need for bioinformatics analysis. While the investments
in these technologies have yet to yield
large numbers of validated biomarkers,
they have allowed researchers to begin
analyzing complex samples in ways
not possible as recently as 5 years ago.
The past couple of years have been
witness to new and imaginative ways to
analyze clinical samples that target the
site of the disorder and may eventually
yield validatable biomarkers with high
sensitivity and specificity.
As the analytical technology
applied to proteomic analysis of
complex biological samples increases
in sensitivity, there is an increasing
burden placed on the standardization
of sample collection and handling.
Artifacts arising from nonspecific
proteolysis and protein degradation are
likely to be quite variable depending
on details such as sampling-handling
parameters. A recent study showing the
ability to classify solid tumors based
on the signature peptides produced by
the action of exopeptidases postextraction (21), underscores the need
for consistent sample handling prior
to analysis. Even for samples such as
FFPE tissues, the variability introduced
by formalin-fixation time and length
of storage are not yet well understood.
The effects (and potential artifacts)
introduced by sample acquisition,
storage, and processing will need to
be measured in a systematic manner
within a well-controlled study.
Although the application of MS
for protein biomarker investigations is
arguably the most powerful discoverydriven methodology, the ultimate goal is
to mobilize such discoveries to routine
clinical application for in vitro diagnostic
assays. Although these MS-based applications exist, namely the powerful assay
Vol. 40, No. 6 (2006)

to screen newborns for inborn errors
of metabolism (22), there are many
hurdles to overcome in the translation
of MS technology to the development
of routine clinical diagnostic assays
of protein biomarkers from complex
matrices. In perhaps a more idealized
biomarker developmental workflow, high
affinity reagents, such as monoclonal
antibodies, would be generated against
lead biomarkers forthcoming from
MS-based discovery-driven investigations. These reagents have a long and
rigorously validated history of use in
in vitro diagnostic applications and in
large part are likely to contribute to a
shorter trajectory to clinical adoption of
newly discovered biomarkers, especially
when the validation and regulatory due
diligence that underpin such translations is considered. The production of
an antibody with high affinity and specificity for an antigen, however, is never a
guarantee. It will not be surprising if MS
begins to play a larger role in biomarker
validation as the analytical attributes (i.e.,
sensitivity, resolution, direct detection,
etc.) that make it the premier technology
for proteome characterization also
enable it to interrogate specific species in
complex mixtures (23).
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